Azerbaijan, Baku, Mar. 5/ Trend F.Milad/
Iran has succeeded in producing a certain drug, named Glatiramer, for multiple sclerosis (MS) patients, and ended Israel's monopoly in the market, Fars news agency quoted Iran's Food and Drug Organization as saying.
Ahmad Sheibani added that the drug was sold at $64 in the European market, but it will be supplied to the domestic market at just $28.5.
Glatiramer acetate is one of the disease modifying drugs licensed for relapsing remitting multiple sclerosis. Studies have shown that on average, glatiramer acetate reduces the MS relapse rate by about a third.